Patents by Inventor Kenton Longenecker
Kenton Longenecker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9856253Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.Type: GrantFiled: April 15, 2016Date of Patent: January 2, 2018Assignee: AbbVie, Inc.Inventors: Eric C. Breinlinger, Phil B. Cox, Justin Dietrich, Kristine E. Frank, Michael M. Friedman, Huan-Qui Li, Kenton Longenecker, Augustine Osuma, Ann Marie Rowley, Anil Vasudevan, Noel Wilson
-
Patent number: 9758511Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.Type: GrantFiled: February 19, 2016Date of Patent: September 12, 2017Assignee: AbbVie Inc.Inventors: Michael L. Curtin, Kenton Longenecker, Todd M. Hansen, Richard F. Clark, Bryan Sorensen, Howard R. Heyman, Zhiqin Ji
-
Publication number: 20170135994Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.Type: ApplicationFiled: October 8, 2015Publication date: May 18, 2017Applicant: AbbVie Inc.Inventors: Richard F. Clark, Bryan Sorensen, Augustine T. Osuma, Robin Frey, Kenton Longenecker, George Doherty, Michael L. Curtin, Michael Michaelides, Ramzi Sweis, Marina Pliushchev, Andrew Judd, Todd Hansen, Howard R. Heyman
-
Publication number: 20170065575Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.Type: ApplicationFiled: November 21, 2016Publication date: March 9, 2017Inventors: Todd M. Hansen, Kenton Longenecker, Howard R. Heyman, Michael L. Curtin, Richard F. Clark, Bryan Sorensen, Zhiqin Ji, Kevin Woller, George Doherty, Robin Frey
-
Publication number: 20160304517Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.Type: ApplicationFiled: April 15, 2016Publication date: October 20, 2016Inventors: Eric C. Breinlinger, Phil B. Cox, Jerome Daanen, Justin Dietrich, Stevan Djuric, Amanda W. Dombrowski, Kristine E. Frank, Michael M. Friedman, Arthur Gomtsyan, Huan-Qui Li, Kenton Longenecker, Augustine Osuma, Ann Marie Rowley, Robert Schmidt, Anil Vasudevan, Noel Wilson
-
Publication number: 20160193209Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.Type: ApplicationFiled: March 11, 2016Publication date: July 7, 2016Applicant: AbbVie Inc.Inventors: Ramzi F. Sweis, Michael L. Curtin, Marina A. Pliushchev, Todd M. Hansen, Kenton Longenecker
-
Publication number: 20160184281Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.Type: ApplicationFiled: October 8, 2015Publication date: June 30, 2016Applicant: ABBVIE INC.Inventors: Richard F. Clark, Bryan Sorensen, Augustine T. Osuma, Robin Frey, Kenton Longenecker, George Doherty, Michael L. Curtin, Michael Michaelides, Ramzi Sweis, Marina Pliushchev, Andrew Judd, Todd Hansen, Howard R. Heyman
-
Publication number: 20160184282Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.Type: ApplicationFiled: October 8, 2015Publication date: June 30, 2016Applicant: AbbVie Inc.Inventors: Richard F. Clark, Bryan Sorensen, Augustine T. Osuma, Robin Frey, Kenton Longenecker, George Doherty, Michael L. Curtin, Michael Michaelides, Ramzi Sweis, Marina Pliushchev, Andrew Judd, Todd Hansen, Howard R. Heyman
-
Publication number: 20160168134Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.Type: ApplicationFiled: February 19, 2016Publication date: June 16, 2016Applicant: AbbVie Inc.Inventors: Michael L. Curtin, Kenton Longenecker, Todd M. Hansen, Richard F. Clark, Bryan Sorensen, Howard R. Heyman, Zhiqin Ji
-
Patent number: 9334264Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.Type: GrantFiled: May 10, 2013Date of Patent: May 10, 2016Assignee: AbbVie Inc.Inventors: Ramzi F. Sweis, Michael L. Curtin, Marina A. Pliushchev, Todd M. Hansen, Kenton Longenecker
-
Patent number: 9296723Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.Type: GrantFiled: May 10, 2013Date of Patent: March 29, 2016Assignee: AbbVie Inc.Inventors: Michael L. Curtin, Kenton Longenecker, Todd M. Hansen, Richard F. Clark, Bryan Sorensen, Howard R. Heyman, Zhiqin Ji
-
Patent number: 9193723Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.Type: GrantFiled: May 10, 2013Date of Patent: November 24, 2015Assignee: AbbVie Inc.Inventors: Richard F. Clark, Bryan Sorensen, Augustine T. Osuma, Robin Frey, Kenton Longenecker, George Doherty, Michael L. Curtin, Michael R. Michaelides, Ramzi F. Sweis, Marina A. Pliushchev, Andy Judd, Todd M. Hansen, Howard R. Heyman
-
Patent number: 9187472Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.Type: GrantFiled: May 10, 2013Date of Patent: November 17, 2015Assignee: AbbVie Inc.Inventors: Richard F. Clark, Bryan Sorensen, Augustine T. Osuma, Robin Frey, Kenton Longenecker, George Doherty, Michael L. Curtin, Michael R. Michaelides, Ramzi F. Sweis, Marina A. Pliushchev, Andy Judd, Todd M. Hansen, Howard R. Heyman
-
Publication number: 20150141398Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.Type: ApplicationFiled: January 23, 2015Publication date: May 21, 2015Inventors: Todd M. Hansen, Kenton Longenecker, Howard R. Heyman, Michael L. Curtin, Richard F. Clark, Bryan Sorensen, Zhiqin Ji, Kevin Woller, George Doherty, Robin Frey
-
Patent number: 8975398Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.Type: GrantFiled: May 10, 2013Date of Patent: March 10, 2015Assignee: AbbVie Inc.Inventors: Todd M. Hansen, Kenton Longenecker, Howard R. Heyman, Michael L. Curtin, Richard F. Clark, Bryan Sorensen, Zhiqin Ji, Kevin Woller, George Doherty, Robin Frey
-
Publication number: 20140336167Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.Type: ApplicationFiled: May 10, 2013Publication date: November 13, 2014Applicant: ABBVIE INC.Inventors: Ramzi F. Sweis, Michael L. Curtin, Marina A. Pliushchev, Todd M. Hansen, Kenton Longenecker
-
Publication number: 20130303510Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.Type: ApplicationFiled: May 10, 2013Publication date: November 14, 2013Applicant: ABBVIE INC.Inventors: Todd M. Hansen, Kenton Longenecker, Howard R. Heyman, Michael L. Curtin, Richard F. Clark, Bryan Sorensen, Zhiqin Ji, Kevin Woller, George Doherty, Robin Frey
-
Publication number: 20130303509Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.Type: ApplicationFiled: May 10, 2013Publication date: November 14, 2013Applicant: ABBVIE INC.Inventors: Todd M. Hansen, Kenton Longenecker, Howard R. Heyman, Michael L. Curtin, Richard F. Clark, Bryan Sorensen, Zhiqin Ji, Kevin Woller, George Doherty, Robin Frey
-
Publication number: 20130303511Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.Type: ApplicationFiled: May 10, 2013Publication date: November 14, 2013Applicant: AbbVie Inc.Inventors: Richard F. Clark, Bryan Sorensen, Augustine T. Osuma, Robin Frey, Kenton Longenecker, George Doherty, Michael L. Curtin, Michael R. Michaelides, Ramzi F. Sweis, Marina A. Pliushchev, Andy Judd, Todd M. Hansen, Howard R. Heyman
-
Publication number: 20130303508Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.Type: ApplicationFiled: May 10, 2013Publication date: November 14, 2013Applicant: ABBVIE INC.Inventors: Richard F. Clark, Bryan Sorensen, Augustine T. Osuma, Robin Frey, Kenton Longenecker, George Doherty, Michael L. Curtin, Michael R. Michaelides, Ramzi F. Sweis, Marina A. Pliushchev, Andy Judd, Todd M. Hansen, Howard R. Heyman